The Filing Desk

CG Oncology

CGON · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

CGON · Last close · November 13, 2026
$74.40
Value CG Oncology yourself

CG Oncology's revenue rose 254.7% to $4 million in fiscal 2025. Its operating margin was −4,722.1%, up from −10,067.2% a year earlier. Free cash flow was −$132 million. The diluted share count rose 23.7%.

CG Oncology, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001193125-26-079498 Updated
Revenue
$4M
254.7%
Operating margin
−4,722.1%
5345.1 pts
Net income
−$161M
 
Free cash flow
−$132M
 
Return on equity
−21.7%
7.2 pts
Market cap
$6.6B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What CG Oncology does

CG Oncology is a late-stage clinical biopharmaceutical company, which means it is testing a medicine in large trials and has no approved product yet. It has one product candidate, cretostimogene grenadenorepvec, a treatment made from a virus that is designed to kill cancer cells directly and to prompt the immune system to attack the tumor.

The target is bladder cancer that has not yet grown into the muscle wall (non-muscle invasive bladder cancer). Its main Phase 3 trial, BOND-003 Cohort C, covers high-risk patients whose cancer did not respond to the standard BCG treatment. For these patients, the next step is usually removal of the whole bladder. CG Oncology began submitting an application to the U.S. Food and Drug Administration in late 2025 and expects to finish it in 2026. A second Phase 3 trial, PIVOT-006, tests the treatment in intermediate-risk patients after tumor removal.

It relies on a partner, Biovire, and other third parties to make the drug and to run its trials.

Its biggest risks, as it describes them

  • It depends entirely on cretostimogene, its only product candidate.
  • Its approach to treating cancer is new, so the time and cost of development and approval are hard to predict.
  • Trial results may be unfavorable, or the drug may cause side effects that delay or block approval.
  • It relies on third parties, including Biovire, to run trials and make and ship the drug.
From CG Oncology's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

CG Oncology lost money in fiscal 2025: a net loss of $161 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments188742742
Debt incl. finance leases—03
Net debt (negative means net cash)—−742−739
Net debt to EBITDA———
Debt to equity—0.0x0.0x
Interest coverage−147.5x—−1,852.2x
Current ratio13.6x35.3x24.6x
Quick ratio13.6x35.3x24.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project CG Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What CG Oncology says to expect

  • Cash position: funding of operationsThe Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 6, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $24.8 million of CG Oncology shares on the open market, and 2 insiders sold $4.8 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 15, 2026Leonard E PostDirectorSold plan1,000$72.98$72,980Form 4
Aug 14, 2026Leonard E PostDirectorSold plan1,000$74.54$74,540Form 4
Jul 15, 2026Leonard E PostDirectorSold plan1,000$71.17$71,170Form 4
Jul 10, 2026James MulayDirectorSold plan24,165$75.16$1.8 millionForm 4
Jun 25, 2026Brian Guan-Chyun LiuDirectorBought plan371,085$66.87$24.8 millionForm 4
Jun 24, 2026Leonard E PostDirectorSold plan5,000$70.00$350,000Form 4
Jun 22, 2026Leonard E PostDirectorSold plan5,000$65.00$325,000Form 4
Jun 15, 2026James MulayDirectorSold plan1,964$60.12$118,076Form 4
Jun 4, 2026Leonard E PostDirectorSold plan1,000$54.50$54,500Form 4
Apr 17, 2026James MulayDirectorSold plan15,600$73.01$1.1 millionForm 4
Mar 16, 2026James MulayDirectorSold plan1,964$63.50$124,714Form 4
Jan 9, 2026James MulayDirectorSold plan11,145$52.47$584,799Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score—2 of 8
Rule of 40−6,472.9%−3,024.5%
Altman Z''40.3623.13
Accruals ratio−1.9%−3.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Pass
Cash from operations exceeds net incomePassPass
Debt fell relative to assets—Fail
Current ratio rosePassFail
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets—Fail
F-score—2 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put CG Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CG OncologyFY25254.7%−4,722.1%−3,279.2%——2
CRISPR TherapeuticsFY25−90.6%−18,933.7%−9,855.5%———Compare
Prime MedicineFY2555.3%−4,498.1%−3,607.4%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue014
Revenue growth—458.3%254.7%
Gross profit———
Research and development4682117
Operating income−55−115−191
Net income−49−88−161
Diluted EPS (US$)−15.65−1.41−2.08
Diluted shares (millions)46277
Cash flow
Cash from operations−46−79−132
Capital expenditure—00
Free cash flow—−79−132
Dividends paid000
Share buybacks000
Acquisitions0022
Stock-based compensation21127
Balance sheet at fiscal year end
Cash and short-term investments188742742
Debt incl. finance leases—03
Total assets199755792
Total liabilities142139
Shareholders' equity−123733753
Margins and ratios
Gross margin———
Operating margin−27,180.9%−10,067.2%−4,722.1%
Net margin−23,827.0%−7,729.5%−3,985.0%
Free cash flow margin—−6,931.3%−3,279.2%
Rule of 40 (growth + FCF margin)—−6,472.9%−3,024.5%
Return on capital———
Return on equity—−28.9%−21.7%
Return on assets—−18.4%−20.8%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: CG Oncology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with CG Oncology.